Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis

A new drug Bedaquiline, a diarylquinoline agent has been approved by the Food and Drug Administration for the treatment of pulmonary multidrug-resistant tuberculosis. It has been given approval for use along with the basic regimen with only conditional access through the National Program for tubercu...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshkar, Anuradha T, Shirure, Prashant A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516320/
https://www.ncbi.nlm.nih.gov/pubmed/36185922
http://dx.doi.org/10.7759/cureus.28519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516320/
https://www.ncbi.nlm.nih.gov/pubmed/36185922
http://dx.doi.org/10.7759/cureus.28519

Ejemplares similares